Establishment of treatment method using activated MSC for autoimmune myocarditis

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08568
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: Osaka Habikino Medical Center (2020-2021); Fujita Health University (2019)
• Principal Investigator: Okura hanayuki 地方独立行政法人大阪府立病院機構大阪はびきの医療センター(臨床研究センター), 次世代創薬創生センター, 研究員(移行) (20589684)
• Co-Investigator(Kenkyū-buntansha): 松山 晃文 地方独立行政法人大阪府立病院機構大阪はびきの医療センター(臨床研究センター), 次世代創薬創生センター, センター長 (10423170)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 自己免疫性心筋炎 / 抗炎症 / 毛細血管再構築 / 末梢神経再生

Outline of Final Research Achievements

Therapeutic strategies for autoimmune myocarditis are anti-inflammatory in the acute phase and myocardial tissue regeneration in the chronic phase. Regarding the anti-inflammatory effect, priming of MSC increased PGE2 synthase and G-CSF about 10 times or more about 1000 times or more, respectively. Arterial and blood vessels, and peripheral nerve were examined by markers in the specimens. The primed MSC administration augmented the number of positive arterial and venous vessels, and NF68 than those of naive MSC administration, indicating that primed MSC repairs and regenerates arteries and veins and peripheral nerve innervation that are essential for repairing chronically injured tissue. These results hinted us that the primed MSC could improve the prognosis of autoimmune myocarditis.

Free Research Field

再生医療

Academic Significance and Societal Importance of the Research Achievements

活性化MSCは自己免疫性心筋炎への新規治療法となり、急性期の抗炎症、慢性期の血流回復、遠隔期の神経支配回復による予後改善に寄与すると想定される。